Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tilsotolimod in refractory solid tumors
NCT03052205Phase 1Completed
- Sponsor
- Aceragen, Inc.
- Start
- Jun 2017
- Primary completion
- Jul 2019
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of tilsotolimod in solid tumor and melanoma, sponsored by Aceragen, Inc. Primary endpoints: Recommended Phase 2 Dose at 51 weeks, Objective Response Rate at 51 weeks and 1 more. Started Jun 2017; status: completed.
02
Drugs
tilsotolimod
03
Conditions
solid tumormelanoma
Beyond the preview
Go deeper on NCT03052205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03052205.